The CPHI – 14th Annual Pharma IPR India Conference was organised by Informa Markets from March 4-6, 2025, in Mumbai, bringing together industry experts to discuss critical patent and regulatory issues shaping the industry. Some of the key discussions centred on patent strategy for the US market, the role of AI in intellectual property rights (IPR), data management challenges in pharmaceutical litigation, and strategies for defending against infringement claims. The conference also provided valuable insights into patent linkage regulations across the US, Europe, the UK, and India, as well as patent rule amendments and their implications for the pharmaceutical industry.
LexOrbis Partner Avi Garg participated as a panellist in the session โ๐๐บ๐ฝ๐ผ๐๐ฒ๐ฟ๐ถ๐ป๐ด ๐๐ป๐ป๐ผ๐๐ฎ๐๐ถ๐ผ๐ป: ๐๐ป๐๐ฒ๐น๐น๐ฒ๐ฐ๐๐๐ฎ๐น ๐ฃ๐ฟ๐ผ๐ฝ๐ฒ๐ฟ๐๐ ๐ฆ๐๐ฟ๐ฎ๐๐ฒ๐ด๐ถ๐ฒ๐ ๐ถ๐ป ๐๐บ๐ฒ๐ฟ๐ด๐ถ๐ป๐ด ๐ฃ๐ต๐ฎ๐ฟ๐บ๐ฎ ๐๐ฐ๐ผ๐ป๐ผ๐บ๐ถ๐ฐ๐โ. He shared insights on how emerging markets are reshaping IP frameworks, the role of regulatory compliance, the importance of international partnerships in pharma innovation, and customised IP strategies for different regions.
The event was also attended by LexOrbis Managing Partner Manisha Singh and Managing Associates Akash Ghayal and Paulome Mehta, who engaged in discussions on the evolving pharma IP landscape and its global implications.